Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
)'s Avastin as Good as
)'s Lucentis for AMD
7/19/2013 7:44:44 AM
Staying up-to-date has never been simpler. Sign up for the
free GenePool newsletter
Published in the Lancet on Friday, a trial has been claiming that the NHS should make use of an unlicensed drug, cheaper than the licensed one, to treat people at risk of going blind. Since, the same could help it save almost £84m or more each year. It was being questioned if Avastin, the cancer drug, was safe to cure people suffering from wet age-related macular degeneration (AMD).
Help employers find you! Check out all the
post your resume
(RHHBY) to Spend $105 Million on Swiss Training Center
(CELG)'s Revlimid Improves Survival in Blood Cancer Patients
(AZN) to Share Drug Research Data
(NVS) Drug Study Data Manipulated:
Kyoto Prefectrual University of Medicine
Constitution Medical Investors, Inc.
for $220 Million
Pacira Pharmaceuticals, Inc.
Release: New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen
(NVS) Ex-Chairman to Rake in $25,000 a Day for the Next Three Years
Presents Data on Enhanced Topical Ocular Delivery of a Receptor Tyrosine Kinase Inhibitor
(NVS) Over Marketing of Its Gilenya MS Pill
Advanced Cell Technology
Treats First Patient With Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
comments powered by Disqus.
comments powered by
Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Clinical - Post-Approval (World)